Crofelemer Production Cost Reports

The report provides a detailed analysis essential for establishing a Crofelemer production plant. It encompasses all critical aspects necessary for Crofelemer production, including the cost of Crofelemer production, Crofelemer plant cost, Crofelemer production costs, and the overall Crofelemer production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Crofelemer production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Crofelemer is a plant-derived pharmaceutical compound that finds specific applications in the healthcare and pharmaceutical industries. It is a purified oligomeric proanthocyanidin mixture derived from natural catechins and gallocatechins. It is primarily used as an antidiarrheal agent, especially for the treatment of non-infectious diarrhoea in patients receiving antiretroviral therapy for HIV/AIDS. It works by targeting specific chloride channels in the gut to help regulate the flow of water and electrolytes, which helps reduce the frequency and urgency of bowel movements. It is a unique drug, as it acts locally in the digestive system without being absorbed into the bloodstream, which lowers the risk of side effects. It is also explored for managing diarrhoea caused by chemotherapy, irritable bowel syndrome, and other gastrointestinal conditions. In addition, Crofelemer is used in clinical research related to gastrointestinal disorders and electrolyte balance.

The primary factor that drives the market for Crofelemer is its use as a non-opioid treatment option for chronic diarrhoea, which significantly promotes its demand in the medical and healthcare sectors. Its application as a plant-based antidiarrheal agent to treat diarrhoea in people with HIV/AIDS who are on antiretroviral therapy largely boosts its demand in the pharmaceutical industry.

Its usage for regulating chloride ion channels in the intestines to help reduce excessive fluid loss without affecting normal gut movement also boosts its demand in the healthcare sector. Its demand as a prescription medication that helps in improving the quality of life for long-term HIV patients also contributes to its market growth. Factors such as supplier credibility, advancements in extraction and formulation methods, environmental considerations, and efficient global distribution networks also significantly impact procurement practices across its major markets. Moreover, industrial Crofelemer procurement is influenced by several factors, including the sourcing and processing of natural raw materials, adherence to regulatory standards, and consistency in product quality.

Raw Material for Crofelemer Production

According to the Crofelemer production plant project report, the major raw materials for Crofelemer production includes Croton lechleri tree.

Production Process of Crofelemer

The extensive Crofelemer production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Crofelemer begins with the sustainable harvesting of red sap, or latex, from the bark of the Croton lechleri tree found in the Amazon rainforest. The plant material is carefully collected and shipped to a production facility, where it undergoes a complex purification process to isolate Crofelemer as the desired product. Then, the resulting high-purity crofelemer is formulated into delayed-release tablets for Mytesi.

Crofelemer appears as a reddish-brown colored material, while the commercial formulation exists as white, oval, enteric-coated, delayed-release tablets. It is a purified oligomeric proanthocyanidin mixture extracted from the bark latex of the South American tree Croton lechleri, and is used as an antidiarrheal agent. Crofelemer is a complex botanical polymer primarily composed of (+)-catechin, (−)-epicatechin, (+)-gallocatechin, and (−)-epigallocatechin monomer units linked in random sequence. The average molecular weight of crofelemer ranges from approximately 2000 to 2300 daltons. The compound is stored at controlled room temperature between 20 degree Celsius and 25 degree Celsius. The compound is administered orally as delayed-release tablets at a dose of 125 mg twice daily for the symptomatic treatment of non-infectious diarrhoea in adult patients with HIV/AIDS receiving antiretroviral therapy. The most common adverse effects include upper respiratory tract infection, bronchitis, cough, flatulence, and increased bilirubin levels. The compound should be swallowed whole without crushing or chewing to maintain the integrity of the delayed-release formulation.